* Absci Corp ABSI.OQ reported a quarterly adjusted loss
of 24
cents per share for the quarter ended September 30, identical
to the same quarter last year. The mean expectation of
seven analysts for the quarter was for a loss of 21 cents per
share. Wall Street expected results to range from -25 cents
to -18 cents per share.
* Revenue rose 128.6% to $1.70 million from a year ago;
analysts
expected $1.75 million.
* Absci Corp's reported EPS for the quarter was a loss of 24
cents.
* The company reported a quarterly loss of $27.4 million.
* Absci Corp shares had risen by 12.0% this quarter and
gained 1.9% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 4.9%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Absci Corp is
7.00
This summary was machine generated from LSEG data November 12 at
03:32 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.21 -0.24 Missed
Jun. 30 2024 -0.19 -0.22 Missed
Mar. 31 2024 -0.21 -0.22 Missed
Dec. 31 2023 -0.25 -0.25 Met